BenchSci Announces Two-Year Enterprise Agreement with Argenx to Advance AI-Driven Preclinical Drug Discovery

BenchSci Announces Two-Year Enterprise Agreement with argenx to Advance AI-Driven Preclinical Drug Discovery

Scientist-led competitive selection deepens BenchSci’s presence in European biopharma TORONTO — BenchSci, a leading provider of AI software for biopharma research and development, today announced a two-year enterprise agreement with argenx, a global immunology innovation company, to deploy EMET, BenchSci’s agentic research environment for preclinical drug discovery, within the organization. Selected through a competitive evaluation […]

Takeda, Weave Bio collaborate on AI-driven automation in drug development

The partnership aims to integrate Weave Bio’s AI tools with Takeda’s regulatory experience to streamline workflows within the regulatory process. The joint effort began with the use of The post Takeda and Weave Bio collaborate on AI-driven automation in drug development appeared first on Pharmaceutical Business review.

Takeda and Weave Bio collaborate on AI-driven automation in drug development

Takeda has entered into a collaboration to introduce Weave Bio’s AI-native regulatory automation platform across 14 ongoing drug development programmes in various global markets. The post Takeda and Weave Bio collaborate on AI-driven automation in drug development appeared first on Hospital Management.

Weave Bio and Takeda Deploy AI Regulatory Automation Across 14 Global Programs

What You Should Know AI-native regulatory software company Weave Bio announced a major enterprise collaboration with global biopharma leader Takeda to deploy its regulatory automation platform across 14 active drug development programs in multiple global markets. The collaboration directly addresses the heavy administrative bottleneck of regulatory dossier authoring, which has historically trapped critical scientific data ...